Carna Biosciences, Inc. (TYO:4572)

Market Cap	6.40B
Revenue (ttm)	598.71M
Net Income (ttm)	-2.28B
Shares Out	19.10M
EPS (ttm)	-123.86
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	149,900
Average Volume	179,260
Open	331.00
Previous Close	335.00
Day's Range	317.00 - 335.00
52-Week Range	220.00 - 482.00
Beta	0.50
RSI	51.98
Earnings Date	Aug 5, 2025

About Carna Biosciences

Carna Biosciences, Inc., a clinical-stage biopharmaceutical company, discovers and develops drug therapies to treat unmet medical needs in Japan. Its products include kinase proteins, substrates, Luciferase PPI stable cell lines, kinase assay kits, peptide substrate, mobility shifty assay, and lipid kinase panels. The company also offers profiling, NanoBRET TE intracellular kinase cell-based assay, protein detection assays. It also focuses on developing products for the treatment of various diseases, such as AS-0141, an orally bioavailable smal...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2003
• Employees: 63
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4572

Financial Performance

In 2024, Carna Biosciences's revenue was 636.00 million, a decrease of -60.86% compared to the previous year's 1.63 billion. Losses were -2.18 billion, 89.1% more than in 2023.